Floatz logo

Dextromethorphan

Facial Neuralgia

National Institute of Dental and Craniofacial Research (NIDCR)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Facial Neuralgia cohort.

Asset / SponsorPhaseRating
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
HCA Florida North Florida Hospital
Phase 3B
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
HCA Florida North Florida Hospital
Phase 3B
LIDOCAINE
Mahidol University
Phase 1CC
AUTOLOGOUS CONDITIONED PLASMA
University of Calgary
Phase 1CC
LIDOCAINE
University of Calgary
Phase 1CC
Onabotulinum Toxin A
Tanta University
N/AD

Same molecule, other indications

Dextromethorphan is also rated in:

Pseudobulbar Affect (PBA)Dormant
BBB
Indicative ·
75 / 100
View asset →
stroke disorderDormant
BBB
Indicative ·
73 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →